Some achieve greater reductions depending on dose, adherence, metabolism, and lifestyle changes such as diet and activity
Amgen has developed a GLP-1/GIP drug that is given monthly, while Intracia is working on an agent that is injected every six months
Work out what to replace, and how, with your provider
1) GLP-1: appetite control + slower digestion GLP-1 activation (the pathway used by semaglutide/Wegovy) helps people feel fuller sooner, reduces appetite, and slows gastric emptying often reducing snacking and lowering overall intake
A stimulant laxative that works by directly triggering contractions in the colon wall
These peptides could represent the next evolution in obesity pharmacotherapytargeting multiple hormone receptors for lasting results.